Lixte Biotechnology Holdings, INC

Nomad Power Solutions, Inc. announced its common stock is now available for options trading on the Cboe Options Exchange under the symbol NMAD.

Nomad Power Solutions announces a significant upgrade to its Voyager mobile energy storage series, increasing capacity by up to 56% across its Eagle and Falcon models to 2.025 MWh without altering the physical footprint or deployment time.

Lixte Biotechnology Holdings, Inc. has completed its merger with Nomad Transportable Power Systems, Inc., rebranding to Nomad Power Solutions, Inc. and changing its ticker symbol to NMAD, signaling a strategic shift into the AI energy infrastructure market.

Lixte Biotechnology Holdings, Inc. has provided a $6.5 million loan to NOMAD Transportable Power Systems, Inc. ahead of their acquisition, expected to close around July 1, 2026.

Lixte Biotechnology Holdings, Inc. announced a definitive agreement to acquire Nomad Transportable Power Systems, Inc., a leader in mobile battery energy storage systems, and will be renamed NOMAD Power Solutions.

Lixte Biotechnology Holdings, Inc. has successfully closed a registered direct offering of common stock and pre-funded warrants, raising approximately $16.6 million in gross proceeds.

Nomad Power Solutions, Inc. (formerly Lixte Biotechnology Holdings, Inc.) reported its Q2 2026 results, highlighting a strategic shift into AI energy infrastructure and the completion of its merger with NOMAD Transportable Power Systems, Inc.

Lixte Biotechnology Holdings, Inc. reported a net loss of $1.99 million for Q1 2026, with significant increases in R&D and G&A expenses, while cash reserves decreased.

Lixte Biotechnology Holdings, Inc. reports significant capital raises and Nasdaq compliance, despite increased net losses and a clinical trial pause due to serious adverse events.

Lixte Biotechnology Holdings, Inc. reported reduced losses and successful capital raises, securing its Nasdaq listing, but faces a clinical trial hold due to serious adverse events.

Lixte Biotechnology Holdings reports a net loss for Q1 2025 and highlights its ongoing clinical trials and the necessity for additional capital to continue operations.

Lixte Biotechnology reported a net loss of $986,030 for Q3 2024 and is facing substantial doubt about its ability to continue as a going concern, along with Nasdaq listing compliance challenges.

Lixte Biotechnology Holdings, Inc. reported a significantly wider net loss in 2025, driven by increased administrative costs and digital asset losses, while strategically acquiring a proton therapy system and navigating clinical trial developments.

Lixte Biotechnology Holdings provides an update on its clinical-stage biopharmaceutical activities and financial standing in its annual report, highlighting ongoing trials and the need for future capital.

Lixte Biotechnology Holdings, a clinical-stage biopharmaceutical company, released its 2023 annual report, detailing ongoing clinical trials and financial status.

Lixte Biotechnology Holdings, Inc. reports that Chief Financial Officer Peter Stazzone received 50,000 restricted stock units (RSUs) on July 1, 2026, vesting upon achievement of performance conditions.

Lixte Biotechnology Holdings, Inc. CEO Geordan Pursglove was granted 350,000 restricted share units (RSUs) that have vested upon achievement of performance conditions.

Lixte Biotechnology Holdings, Inc. Director Guy Primus received 15,000 restricted share units (RSUs) that have vested.

Michael Holloway, a Director at Lixte Biotechnology Holdings, Inc., received 15,000 restricted share units (RSUs) that have vested.

Lixte Biotechnology Holdings, Inc. reports that Director Lourdes Felix was granted 30,000 restricted share units (RSUs) that have vested.

Lixte Biotechnology Holdings, Inc. reports that Director Stuart D. Porter was granted 25,000 restricted stock units (RSUs) on May 29, 2026, vesting over time.

Nomad Power Solutions, Inc. is holding a special meeting on September 4, 2026, to vote on key proposals including a stock issuance, an amendment to its stock incentive plan, and director elections.

Lixte Biotechnology Holdings, Inc. has filed a definitive proxy statement with the SEC.

Lixte Biotechnology Holdings, Inc. will hold its 2025 Annual Meeting to elect directors, ratify auditors, and vote on a significant increase to its 2020 Stock Incentive Plan, proposing to add 2.75 million shares for a total of 3.5 million.

Lixte Biotechnology Holdings, Inc. has filed a definitive proxy statement with the SEC.

Lixte Biotechnology Holdings will hold its 2024 Annual Meeting of Stockholders virtually on December 19, 2024, to vote on director elections, auditor ratification, and executive compensation.

Lixte Biotechnology Holdings, Inc. has completed two significant capital raises totaling $6.55 million to address its financial needs and Nasdaq listing compliance, while facing ongoing clinical trial hurdles and a 'going concern' warning from auditors.

Lixte Biotechnology Holdings, Inc. is undertaking a public offering of up to 7.69 million shares and pre-funded warrants to secure vital capital for operations and clinical trials, while simultaneously grappling with a Nasdaq compliance deadline and a significant clinical trial pause due to serious adverse events.

Lixte Biotechnology Holdings, a clinical-stage biopharmaceutical company, has filed an S-1 registration statement for a public offering of common stock and pre-funded warrants to raise capital, primarily to regain Nasdaq compliance and fund its operations, as it faces significant financial losses and challenges in its cancer therapy clinical trials.

Lixte Biotechnology Holdings files an amendment to its Form S-1 registration statement to correct a hyperlink and register shares for resale by selling stockholders upon exercise of warrants.

Lixte Biotechnology Holdings files an S-1 registration statement to allow selling stockholders to resell shares of common stock issuable upon exercise of warrants obtained in a recent financing.

Lixte Biotechnology Holdings is offering up to 1,895,734 units, each consisting of common stock or pre-funded warrants and common warrants, aiming to raise approximately $4 million for working capital and general corporate purposes, including advancing its cancer therapies.

Vanguard Capital Management has reported beneficial ownership of 5.02% of Lixte Biotechnology Holdings Inc. common stock as of June 30, 2026.

Strategic EP, LLC and Alexander Chase Deitch have filed a Schedule 13G disclosing a 5.1% beneficial ownership stake in Lixte Biotechnology Holdings, Inc.

Orca Capital AG, a German entity, has disclosed a 4.5% beneficial ownership stake in Lixte Biotechnology Holdings, Inc., holding 120,012 shares of common stock.

Intracoastal Capital LLC, along with Mitchell P. Kopin and Daniel B. Asher, has disclosed a beneficial ownership of 4.99% in Lixte Biotechnology Holdings, Inc. common stock.

Orca Capital AG has filed a Schedule 13G, revealing a passive beneficial ownership of 8.1% in Lixte Biotechnology Holdings, Inc., comprising 217,392 shares.